EA201890584A1 - Новые аналоги инсулина и их применение - Google Patents
Новые аналоги инсулина и их применениеInfo
- Publication number
- EA201890584A1 EA201890584A1 EA201890584A EA201890584A EA201890584A1 EA 201890584 A1 EA201890584 A1 EA 201890584A1 EA 201890584 A EA201890584 A EA 201890584A EA 201890584 A EA201890584 A EA 201890584A EA 201890584 A1 EA201890584 A1 EA 201890584A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- insulin analogue
- application
- insulin analogues
- new insulin
- insulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение относится к новому аналогу инсулина и, более конкретно, к аналогу инсулина с улучшенным in vitro эффектом по сравнению с нативным инсулином, нуклеиновой кислоте, кодирующей указанный аналог, вектору экспрессии, содержащему указанную нуклеиновую кислоту, трансформанту, в которого введен указанный вектор экспрессии, способу получения аналога инсулина из указанного трансформанта, фармацевтической композиции для лечения диабета, содержащей указанный аналог инсулина в качестве активного ингредиента, и способу лечения диабета с использованием указанного аналога инсулина или указанной фармацевтической композиции.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150121819 | 2015-08-28 | ||
PCT/KR2016/009606 WO2017039267A1 (en) | 2015-08-28 | 2016-08-29 | Novel insulin analogs and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201890584A1 true EA201890584A1 (ru) | 2018-08-31 |
Family
ID=58189026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890584A EA201890584A1 (ru) | 2015-08-28 | 2016-08-29 | Новые аналоги инсулина и их применение |
Country Status (17)
Country | Link |
---|---|
US (2) | US10017557B2 (ru) |
EP (1) | EP3341404B1 (ru) |
JP (2) | JP6976930B2 (ru) |
KR (1) | KR20170026284A (ru) |
CN (2) | CN113637065A (ru) |
AR (1) | AR105822A1 (ru) |
AU (1) | AU2016317449B2 (ru) |
CA (1) | CA2999823A1 (ru) |
EA (1) | EA201890584A1 (ru) |
ES (1) | ES2978863T3 (ru) |
NZ (1) | NZ741060A (ru) |
PH (1) | PH12018500690A1 (ru) |
TW (1) | TWI781083B (ru) |
UA (1) | UA125928C2 (ru) |
UY (1) | UY36870A (ru) |
WO (1) | WO2017039267A1 (ru) |
ZA (1) | ZA201802017B (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY36870A (es) * | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
EP3517544A4 (en) | 2016-09-23 | 2020-06-03 | Hanmi Pharm. Co., Ltd. | INSULIN ANALOG HAVING REDUCED INSULIN RECEPTOR BINDING FORCE AND USE THEREOF |
CN110291103A (zh) | 2016-12-05 | 2019-09-27 | 韩美药品株式会社 | 具有弱化的免疫应答的缀合物 |
KR102645064B1 (ko) | 2017-02-03 | 2024-03-08 | 한미약품 주식회사 | 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도 |
AR111341A1 (es) | 2017-03-23 | 2019-07-03 | Hanmi Pharm Ind Co Ltd | Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo |
WO2020130751A1 (ko) | 2018-12-21 | 2020-06-25 | 한미약품 주식회사 | 인슐린 및 글루카곤을 포함하는 약학 조성물 |
CN113453703A (zh) | 2018-12-21 | 2021-09-28 | 韩美药品株式会社 | 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物 |
CN111220604B (zh) * | 2019-12-06 | 2022-03-15 | 东北农业大学 | 一种肉制品中总淀粉含量的测定方法 |
KR102663243B1 (ko) | 2021-08-30 | 2024-05-03 | 국립순천대학교산학협력단 | 트립신 특이적 형광 프로브 및 이의 용도 |
KR102574341B1 (ko) | 2021-08-30 | 2023-09-04 | 순천대학교 산학협력단 | 아미노산 특이적 차단제 및 이의 용도 |
JP2023058903A (ja) * | 2021-10-14 | 2023-04-26 | 株式会社三共 | 遊技機 |
JP2023058900A (ja) * | 2021-10-14 | 2023-04-26 | 株式会社三共 | 遊技機 |
JP2023058901A (ja) * | 2021-10-14 | 2023-04-26 | 株式会社三共 | 遊技機 |
JP2023058902A (ja) * | 2021-10-14 | 2023-04-26 | 株式会社三共 | 遊技機 |
JP2023058899A (ja) * | 2021-10-14 | 2023-04-26 | 株式会社三共 | 遊技機 |
CN114805544B (zh) * | 2022-06-23 | 2022-09-09 | 北京惠之衡生物科技有限公司 | 一种赖脯胰岛素前体、其重组基因工程菌及其构建方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2536040A1 (de) * | 1975-08-13 | 1977-02-24 | Hoechst Ag | Insulin-analoga mit biologischer wirkung |
US5175145A (en) | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
WO1990007522A1 (en) * | 1988-12-23 | 1990-07-12 | Novo Nordisk A/S | Human insulin analogues |
US5716927A (en) * | 1988-12-23 | 1998-02-10 | Novo Nordisk A/S | Insulin analogs having a modified B-chain |
US5422339A (en) | 1991-03-19 | 1995-06-06 | Joslin Diabetes Center, Inc. | Peptides having insulin autoantibody but not insulin receptor binding capacity |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
DE19825447A1 (de) * | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
IL143866A0 (en) * | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
US7238663B2 (en) | 2001-08-28 | 2007-07-03 | Eli Lilly And Company | Pre-mixes of GLP-1 and basal insulin |
AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
MXPA04003569A (es) | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
CA2518776A1 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
CA2526957C (en) | 2003-07-25 | 2011-07-12 | Conjuchem Inc. | Long lasting insulin derivatives and methods thereof |
WO2005047334A1 (en) | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical. Co., Ltd. | Igg fc fragment for a drug carrier and method for the preparation thereof |
EP1917363B1 (en) | 2005-08-16 | 2011-06-22 | Novo Nordisk A/S | Method for making mature insulin polypeptides |
CA2663074A1 (en) * | 2006-09-22 | 2008-03-27 | Novo Nordisk A/S | Protease resistant insulin analogues |
US7790677B2 (en) | 2006-12-13 | 2010-09-07 | Elona Biotechnologies | Insulin production methods and pro-insulin constructs |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
EP2017288A1 (en) | 2007-07-16 | 2009-01-21 | Novo Nordisk A/S | Protease stabilized, pegylated insulin analogues |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
CN101743252A (zh) | 2007-07-16 | 2010-06-16 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、peg化的胰岛素类似物 |
CN101778862B (zh) * | 2007-08-13 | 2014-12-17 | 诺沃-诺迪斯克有限公司 | 快速作用的胰岛素类似物 |
CA2695970A1 (en) | 2007-08-15 | 2009-02-19 | Novo Nordisk A\S | Insulin analogues with an acyl and aklylene glycol moiety |
CN101157725B (zh) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | 人胰岛素类似物的制备方法及用途 |
EP2209800B1 (en) | 2007-11-16 | 2013-07-24 | Novo Nordisk A/S | Stable pharmaceutical compositions comprising liraglutide and degludec |
NZ586589A (en) | 2008-01-09 | 2012-04-27 | Sanofi Aventis Deutschland | Novel insulin analogues having an extremely delayed time-action profile |
BRPI0907371A2 (pt) | 2008-01-09 | 2015-11-24 | Sanofi Aventis Deutschland | derivados de insulina com um perfil de tempo-ação muito retardado |
DE102008025008A1 (de) | 2008-05-24 | 2009-11-26 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
US9260502B2 (en) * | 2008-03-14 | 2016-02-16 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
HUE032284T2 (en) | 2008-03-18 | 2017-09-28 | Novo Nordisk As | Protease-stabilized, acylated insulin analogues |
WO2009129250A2 (en) | 2008-04-14 | 2009-10-22 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
CA2722168A1 (en) * | 2008-04-22 | 2009-10-29 | Case Western Reserve University | Isoform-specific insulin analogues |
BR122013025625B1 (pt) | 2008-10-17 | 2021-08-03 | Sanofi-Aventis Deutschland Gmbh | Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo |
CN102245624B (zh) | 2008-12-19 | 2016-08-10 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
CN102256992B (zh) | 2008-12-19 | 2015-04-22 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物 |
PE20120514A1 (es) | 2009-03-27 | 2012-05-14 | Glaxo Group Ltd | Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica |
WO2011028813A2 (en) | 2009-09-01 | 2011-03-10 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
ES2676373T3 (es) | 2009-11-13 | 2018-07-19 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
KR101058209B1 (ko) | 2009-12-30 | 2011-08-22 | 전자부품연구원 | Ofdm 방식의 디지털 방송 시스템의 빠른 동기 방법 |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
KR101324828B1 (ko) * | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
KR101330868B1 (ko) | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
AU2011268327B2 (en) * | 2010-06-16 | 2016-02-25 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
CA2806399A1 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
KR20120013727A (ko) | 2010-08-06 | 2012-02-15 | 삼성전자주식회사 | 디스플레이장치 및 그 제어방법 |
JP2014504597A (ja) | 2011-01-20 | 2014-02-24 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体とインスリン類似体の組合せ物 |
WO2012116818A1 (en) | 2011-03-02 | 2012-09-07 | Oerlikon Trading Ag, Trübbach | Sliding component coated with metal-comprising carbon layer for improving wear and friction behavior by tribological applications under lubricated conditions |
CN102675452B (zh) | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
MX337474B (es) | 2011-05-03 | 2016-03-04 | Barrday Inc | Panel antibalistico. |
UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
JP6182134B2 (ja) | 2011-06-02 | 2017-08-16 | オプコ バイオロジクス リミテッド | 長時間作用型glp−1/グルカゴン受容体アゴニスト |
DK2718318T3 (en) | 2011-06-10 | 2018-11-05 | Hanmi Science Co Ltd | New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these |
SG10201605006XA (en) | 2011-06-17 | 2016-08-30 | Hanmi Science Co Ltd | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
US9165768B2 (en) | 2011-12-16 | 2015-10-20 | Lg Innotek Co., Ltd. | Method for deposition of silicon carbide and silicon carbide epitaxial wafer |
JP2015507916A (ja) | 2012-01-20 | 2015-03-16 | ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University | グルタミン酸安定化インスリン類似体 |
EP2820150A1 (en) * | 2012-03-01 | 2015-01-07 | Novo Nordisk A/S | N-terminally modified oligopeptides and uses thereof |
KR101665009B1 (ko) | 2012-03-09 | 2016-10-11 | 한미사이언스 주식회사 | 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
SG11201503370WA (en) | 2012-11-06 | 2015-05-28 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
PE20191481A1 (es) | 2013-02-26 | 2019-10-18 | Hanmi Pharm Ind Co Ltd | Analogo de insulina novedoso y su uso |
WO2014133327A1 (ko) * | 2013-02-26 | 2014-09-04 | 한미약품 주식회사 | 인슐린 위치 특이적 결합체 |
CA2937168A1 (en) * | 2014-01-20 | 2015-07-23 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
KR101676542B1 (ko) * | 2014-12-30 | 2016-11-16 | 건국대학교 산학협력단 | 프로인슐린의 면역학적 용도 |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
-
2016
- 2016-08-24 UY UY0001036870A patent/UY36870A/es unknown
- 2016-08-25 AR ARP160102602A patent/AR105822A1/es unknown
- 2016-08-25 TW TW105127234A patent/TWI781083B/zh active
- 2016-08-29 EA EA201890584A patent/EA201890584A1/ru unknown
- 2016-08-29 WO PCT/KR2016/009606 patent/WO2017039267A1/en active Application Filing
- 2016-08-29 JP JP2018511151A patent/JP6976930B2/ja active Active
- 2016-08-29 EP EP16842233.5A patent/EP3341404B1/en active Active
- 2016-08-29 KR KR1020160110301A patent/KR20170026284A/ko not_active Application Discontinuation
- 2016-08-29 UA UAA201802993A patent/UA125928C2/uk unknown
- 2016-08-29 ES ES16842233T patent/ES2978863T3/es active Active
- 2016-08-29 NZ NZ741060A patent/NZ741060A/en unknown
- 2016-08-29 US US15/250,459 patent/US10017557B2/en active Active
- 2016-08-29 CN CN202110754369.1A patent/CN113637065A/zh active Pending
- 2016-08-29 CA CA2999823A patent/CA2999823A1/en active Pending
- 2016-08-29 CN CN201680062814.5A patent/CN108350056B/zh active Active
- 2016-08-29 AU AU2016317449A patent/AU2016317449B2/en active Active
-
2018
- 2018-03-27 ZA ZA2018/02017A patent/ZA201802017B/en unknown
- 2018-03-27 PH PH12018500690A patent/PH12018500690A1/en unknown
- 2018-05-25 US US15/990,495 patent/US10647753B2/en active Active
-
2021
- 2021-07-21 JP JP2021120106A patent/JP7252280B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
NZ741060A (en) | 2024-05-31 |
CN108350056B (zh) | 2021-09-21 |
EP3341404A4 (en) | 2019-08-21 |
US10017557B2 (en) | 2018-07-10 |
CN113637065A (zh) | 2021-11-12 |
JP2021168687A (ja) | 2021-10-28 |
WO2017039267A1 (en) | 2017-03-09 |
EP3341404C0 (en) | 2024-04-03 |
TW201710288A (zh) | 2017-03-16 |
EP3341404B1 (en) | 2024-04-03 |
CN108350056A (zh) | 2018-07-31 |
AU2016317449B2 (en) | 2021-01-07 |
UA125928C2 (uk) | 2022-07-13 |
KR20170026284A (ko) | 2017-03-08 |
ZA201802017B (en) | 2019-01-30 |
AU2016317449A1 (en) | 2018-04-19 |
JP7252280B2 (ja) | 2023-04-04 |
PH12018500690A1 (en) | 2018-10-15 |
ES2978863T3 (es) | 2024-09-23 |
CA2999823A1 (en) | 2017-03-09 |
UY36870A (es) | 2017-03-31 |
TWI781083B (zh) | 2022-10-21 |
US10647753B2 (en) | 2020-05-12 |
AR105822A1 (es) | 2017-11-15 |
EP3341404A1 (en) | 2018-07-04 |
JP6976930B2 (ja) | 2021-12-08 |
JP2018526001A (ja) | 2018-09-13 |
US20170066811A1 (en) | 2017-03-09 |
US20180282388A1 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890584A1 (ru) | Новые аналоги инсулина и их применение | |
MX2024001192A (es) | Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos. | |
EA201890343A1 (ru) | Быстродействующие инсулиновые композиции | |
MY161773A (en) | Amylin analogues and pharmaceutical compositions thereof | |
EA201890630A1 (ru) | Антитела против pd-1 и способы их применения | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
CL2016000873A1 (es) | Analogos de glucagon acilado, una composicion que lo comprende; su uso para la fabricacion de un medicamento util para impedir el aumento de peso; un kit y un procedimiento. | |
EA201492053A1 (ru) | Белки фактора роста фибробластов 21 | |
BR112017027567A2 (pt) | proteínas de fusão para inibir a angiogênese | |
EA033399B1 (ru) | Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение | |
EA201691754A1 (ru) | Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение | |
PH12017501486A1 (en) | Nasal powder formulation for treatment of hypoglycemia | |
EA201691374A1 (ru) | Инсулин длительного действия и его применение | |
EA201890776A1 (ru) | Агонисты ppar, соединения, фармацевтические композиции и способы их применения | |
EA201791537A1 (ru) | Фармацевтическая композиция на основе наночастиц доцетаксела-альбумина, способ ее получения и ее применение | |
EA201391488A1 (ru) | Композиции со сниженной вязкостью | |
EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA201790699A1 (ru) | Стабилизированные производные адреномедуллина и их применение | |
BR112017014552A2 (pt) | ?análogo de calcitonina, e, método para produzir uma diminuição nos triglicerídeos no fígado/redução de acúmulo de gordura no fígado? | |
EA201992168A1 (ru) | Аналоги деутетрабеназина, их получение и применение | |
MX2018009676A (es) | Proceso. | |
MX2016012314A (es) | Analagos de apelina ciclicos. | |
EA202090788A1 (ru) | Жидкая композиция для использования в качестве противовоспалительного средства | |
EA201700097A1 (ru) | Пептид для лечения сахарного диабета 2-го типа и его осложнений | |
BR112017022656A2 (pt) | conservação in vitro de células terapêuticas |